The BLA submission in Q4 2026 is the primary catalyst. Monitor for any FDA feedback or regulatory delays. The strong cash runway into Q1 2028 reduces near-term dilution risk. The AURORA NSCLC trial enrollment progress is a secondary catalyst for 2027.
Price Chart
Executive Summary
Candel Therapeutics reported Q2 2026 financial results with a net loss of $38.9M ($0.52 per share), significantly wider than the $4.8M loss in Q2 2025, driven by increased R&D spending ($19.8M vs $7.0M) and a $12.3M non-cash charge from warrant liability revaluation. The company has $201.6M cash, sufficient into Q1 2028, and reiterated plans to submit a BLA for aglatimagene in localized prostate cancer in Q4 2026, with a potential 2027 commercial launch. The stock will move on the BLA submission timeline and phase 3 data readouts, not the pre-revenue financials themselves.
Key Financial Metrics
Key Facts
- Net loss of $38.9M in Q2 2026 vs $4.8M in Q2 2025, driven by higher R&D and a $12.3M non-cash warrant liability charge
- Cash and cash equivalents of $201.6M as of June 30, 2026, expected to fund operations into Q1 2028
- Planning BLA submission for aglatimagene in localized prostate cancer in Q4 2026, with potential 2027 commercial launch
- Pivotal phase 3 data published in The Lancet Oncology showed 39% improvement in prostate cancer-specific disease-free survival
- Activated first trial site for AURORA phase 3 trial of aglatimagene in NSCLC
- Appointed Mark Sims as Chief Commercial Officer to support potential launch
Financial Impact
Net loss widened to $38.9M from $4.8M; cash position $201.6M; no revenue reported
Risk Factors
- BLA submission or approval may be delayed by FDA
- Clinical trial failures in NSCLC or glioblastoma programs
- Cash burn rate increased significantly; future capital raises may be needed beyond Q1 2028
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3344478 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | Press Release | $10.16 | awaiting T+60 | — | $7.79 (−23.33%) |
Sep 30, 2026 26d ago | Press Release | $10.44 | awaiting T+60 | — | $7.79 (−25.38%) |
Sep 10, 2026 6w ago | 8-K | $11.33 | awaiting T+60 | — | $7.79 (−31.24%) |
Sep 9, 2026 6w ago | 8-K | $11.33 | awaiting T+60 | — | $7.79 (−31.24%) |
Aug 15, 2026 10w ago | Institutional Cluster | $12.16 | awaiting T+60 | — | $7.79 (−35.94%) |
Aug 13, 2026 10w ago | 8-K | $11.80 | awaiting T+60 | — | $7.79 (−33.98%) |
Aug 13, 2026 10w ago | Press Release | $11.80 | awaiting T+60 | — | $7.79 (−33.98%) |
Aug 3, 2026 12w ago | Press Release | $10.07 | awaiting T+60 | — | $7.79 (−22.64%) |
Jul 1, 2026 16w ago | Insider Cluster | $9.83 $11.19 | ▲ +13.84% | ▲ +11.04% | $7.79 (−20.75%) |
Jul 1, 2026 16w ago | Insider Cluster | $9.83 $11.19 | ▲ +13.84% | ▲ +11.04% | $7.79 (−20.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers